The Democratic Alliance (DA) said it would write to the Competition Commission and the Medicines Control Council to request that they investigate the market conduct of Aspen Pharmacare, the leading South African pharmaceutical company.
This comes as a response to reports in the United Kingdom and South Africa detailing how staff at Aspen Pharmacare allegedly plotted to dispose of life-saving cancer medication in order to drive up their price across Europe.
The London-based Times newspaper reported allegations that this campaign had seen prices of life-saving cancer treatment inflated by more than 1,000 percent.
“The price rises meant that the cost of Busulfan, used by leukaemia patients, rose from £5.20 to £65.22 a pack in England and Wales during 2013, an increase of more than 1,100 percent. The prices of chlorambucil, also used to treat blood cancer, rose from £8.36 to £40.51 a pack in the same year.”
DA spokesperson on health Wilmot James said the World Bank had already highlighted that the South African pharmaceutical industry was controlled by cartels and operated in an uncompetitive manner, which would have the effect of increasing the cost of medication.
“Given the reports about how the cost of cancer drugs in Europe have been inflated, an investigation by the Competition Commission and the Medicines Control Council must, therefore, look into whether the same tactics are being used in our own country,” James said in a statement.
“It appears to be an effort to manipulate the market for drugs that effectively will put them out of reach for many, if not most.”
James also said the DA would seek clarity from the Competition Commission as to whether they were currently investigating the South African pharmaceutical industry for uncompetitive behaviour and, if so, to make public the findings thereof.
Full Content: E NCA
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
